Investor Relations

News

Date Title and Summary Additional Formats
Toggle Summary Intersect ENT Reports First Quarter 2020 Results
MENLO PARK, Calif. --(BUSINESS WIRE)--May 11, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today reported financial results for the first quarter ended March 31, 2020 .
View HTML
Toggle Summary Intersect ENT Announces $65 Million Convertible Notes Investment from Deerfield Management
MENLO PARK, Calif. --(BUSINESS WIRE)--May 11, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced that it has closed a $65 million convertible notes financing with a fund managed by Deerfield Management
View HTML
Toggle Summary Intersect ENT Reschedules Time of First Quarter 2020 Financial Results Conference Call to 4:30 P.M. ET on May 11, 2020
MENLO PARK, Calif. --(BUSINESS WIRE)--May 8, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced the Company has rescheduled a conference call to discuss its first quarter 2020 financial results to 4:30
View HTML
Toggle Summary Intersect ENT to Present at the 2020 Bank of America Merrill Lynch Global Healthcare Conference
MENLO PARK, Calif. --(BUSINESS WIRE)--May 7, 2020-- Intersect ENT, Inc. (Nasdaq: XENT ), today announced that management will participate in a virtual fireside chat at the Bank of America Merrill Lynch Global Healthcare Conference . The fireside chat will take place on Thursday, May 14, 2020 at
View HTML
Toggle Summary Intersect ENT to Report First Quarter 2020 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Apr. 28, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced that it will release first quarter 2020 financial results on May 11, 2020 .
View HTML
Toggle Summary Intersect ENT Announces Preliminary Revenue for First Quarter 2020 and Provides Business Update in Response to COVID-19 Pandemic
- Preliminary Unaudited First Quarter 2020 Revenue Expected to be $19.5 to $19.8 Million - - Company Withdraws Full Year 2020 Guidance - MENLO PARK, Calif. --(BUSINESS WIRE)--Apr. 13, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat
View HTML
Toggle Summary Intersect ENT Reports Fourth Quarter and Full Year 2019 Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Feb. 24, 2020-- Intersect ENT, Inc. (NASDAQ:XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today reported financial results for the fourth quarter and full year ended December 31, 2019 .
View HTML
Toggle Summary Intersect ENT to Present at the 9th Annual SVB Leerink Global Healthcare Conference
MENLO PARK, Calif. --(BUSINESS WIRE)--Feb. 5, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), today announced that management will participate in the 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020 at the Lotte New York Palace in New York City , and will present in a
View HTML
Toggle Summary Intersect ENT to Report Fourth Quarter and Year 2019 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Feb. 5, 2020-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that it will release fourth quarter and year 2019 financial results on February 24, 2020 .
View HTML
Toggle Summary Intersect ENT Reports Preliminary Full Year 2019 Revenue
MENLO PARK, Calif. --(BUSINESS WIRE)--Jan. 13, 2020-- Intersect ENT, Inc. (NASDAQ: XENT), a company transforming care for patients with ear, nose and throat conditions, today reported preliminary unaudited revenue for the full year ended December 31, 2019 .
View HTML